The Bill & Melinda Gates Foundation has awarded Takeda Pharmaceuticals a $38 million grant to support development of a low-cost polio vaccine.
The study analyzed some 5,000 young females – and found a dramatic reduction in key strains of...
The aftermath of a catastrophic clinical trial in France has raised concerns regarding the lack...
It is ill-advised to take large quantities of these vitamins over long periods of time. Read...
In terms of the potential competition CCX168 may face in the AAV market, GlobalData expects that the drug will hold an advantage over several competitors due to attractive pricing.
The erroneous tests could have led to thousands of misdirected health-care decisions over those two years.
Joseph Papa shed light on the potential strategy for reducing the drug maker's debt load.
Combination approaches have the potential to generate twice as many sales in the recurrent RCC market.
An early review conducted by The Food and Drug Administration (FDA) of Sanofi’s combination diabetes drug iGlarLixi is raising issues related to efficacy.
This drug is projected to be an important source of revenue for Novo Nordisk.
Over the past decade, new strategies in peptide design have launched a wave of peptide therapeutics. Currently, there are approximately 140 peptide therapeutics in clinical development with over 500 in preclinical development, and the commercial market for novel innovative peptide therapeutics is expected to increase to $17.0 billion by 2018.
The drug is expected to bring around $2.5 billion in annual sales by 2020.
Early studies of these drugs have demonstrated very impressive remission rates of up to 90 percent.
All participants presented intriguing viewpoints for this controversial topic.
Diagnosing complex autoimmune diseases and related conditions is a challenging endeavor, as these multifaceted conditions often present with non-specific symptoms across several organ systems. However, emerging RNA-based diagnostic technologies can dramatically reduce the time to diagnosis of complex diseases, including autoimmune disease.
The scope for improvement in the Huntington’s disease space is vast.
Alex Gorsky discussed everything from developing new drugs to establishing an appropriate pricing system for these medications.
The acquisition is expected to close by the end of the third quarter.
Details surrounding this venture are vague.